| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study.
|
J Clin Oncol
|
2013
|
3.26
|
|
2
|
Satellite lesions in patients with small hepatocellular carcinoma with reference to clinicopathologic features.
|
Cancer
|
2002
|
1.43
|
|
3
|
Cisplatin and etoposide as first-line chemotherapy for poorly differentiated neuroendocrine carcinoma of the hepatobiliary tract and pancreas.
|
Jpn J Clin Oncol
|
2010
|
1.42
|
|
4
|
Phase II study of FOLFIRINOX for chemotherapy-naïve Japanese patients with metastatic pancreatic cancer.
|
Cancer Sci
|
2014
|
1.30
|
|
5
|
An early phase II study of S-1 in patients with metastatic pancreatic cancer.
|
Oncology
|
2005
|
1.21
|
|
6
|
A phase II study of S-1 in gemcitabine-refractory metastatic pancreatic cancer.
|
Cancer Chemother Pharmacol
|
2008
|
1.20
|
|
7
|
Randomized phase II study of gemcitabine plus S-1 versus S-1 in advanced biliary tract cancer: a Japan Clinical Oncology Group trial (JCOG 0805).
|
Cancer Sci
|
2013
|
1.20
|
|
8
|
A phase I/II trial of the oral antiangiogenic agent TSU-68 in patients with advanced hepatocellular carcinoma.
|
Cancer Chemother Pharmacol
|
2011
|
1.17
|
|
9
|
Severe drug toxicity associated with a single-nucleotide polymorphism of the cytidine deaminase gene in a Japanese cancer patient treated with gemcitabine plus cisplatin.
|
Clin Cancer Res
|
2005
|
1.14
|
|
10
|
Clinical impact of c-Met expression and its gene amplification in hepatocellular carcinoma.
|
Int J Clin Oncol
|
2012
|
1.08
|
|
11
|
Transarterial chemoembolization failure/refractoriness: JSH-LCSGJ criteria 2014 update.
|
Oncology
|
2014
|
1.06
|
|
12
|
Regular dose of gemcitabine induces an increase in CD14+ monocytes and CD11c+ dendritic cells in patients with advanced pancreatic cancer.
|
Jpn J Clin Oncol
|
2009
|
1.05
|
|
13
|
Phase 1 trial of Wilms tumor 1 (WT1) peptide vaccine and gemcitabine combination therapy in patients with advanced pancreatic or biliary tract cancer.
|
J Immunother
|
2011
|
1.04
|
|
14
|
Prognostic factors in japanese patients with advanced pancreatic cancer treated with single-agent gemcitabine as first-line therapy.
|
Jpn J Clin Oncol
|
2008
|
1.00
|
|
15
|
Liver cryptococcosis manifesting as obstructive jaundice in a young immunocompetent man: report of a case.
|
Surg Today
|
2008
|
0.96
|
|
16
|
Thirty novel genetic variations in the SLC29A1 gene encoding human equilibrative nucleoside transporter 1 (hENT1).
|
Drug Metab Pharmacokinet
|
2006
|
0.96
|
|
17
|
Construction and validation of a prognostic index for patients with metastatic pancreatic adenocarcinoma.
|
Pancreas
|
2011
|
0.95
|
|
18
|
Podoplanin is an inflammatory protein upregulated in Th17 cells in SKG arthritic joints.
|
Mol Immunol
|
2012
|
0.95
|
|
19
|
Population pharmacokinetics of gemcitabine and its metabolite in Japanese cancer patients: impact of genetic polymorphisms.
|
Clin Pharmacokinet
|
2010
|
0.92
|
|
20
|
Analysis of prognostic factors affecting survival after initial recurrence and treatment efficacy for recurrence in patients undergoing potentially curative hepatectomy for hepatocellular carcinoma.
|
Ann Surg Oncol
|
2007
|
0.92
|
|
21
|
Borderline resectable pancreatic cancer: rationale for multidisciplinary treatment.
|
J Hepatobiliary Pancreat Sci
|
2011
|
0.92
|
|
22
|
Phase II study of gemcitabine chemotherapy alone for locally advanced pancreatic carcinoma: JCOG0506.
|
Jpn J Clin Oncol
|
2010
|
0.92
|
|
23
|
Ultrasound-guided percutaneous pancreatic tumor biopsy in pancreatic cancer: a comparison with metastatic liver tumor biopsy, including sensitivity, specificity, and complications.
|
J Gastroenterol
|
2008
|
0.91
|
|
24
|
Spontaneous regression of hepatocellular carcinoma.
|
Int J Clin Oncol
|
2006
|
0.91
|
|
25
|
Prognostic factors in patients with small hepatocellular carcinoma treated by percutaneous ethanol injection.
|
J Gastroenterol Hepatol
|
2002
|
0.91
|
|
26
|
Everolimus for advanced pancreatic neuroendocrine tumours: a subgroup analysis evaluating Japanese patients in the RADIANT-3 trial.
|
Jpn J Clin Oncol
|
2012
|
0.90
|
|
27
|
Twenty novel genetic variations and haplotype structures of the DCK gene encoding human deoxycytidine kinase (dCK).
|
Drug Metab Pharmacokinet
|
2008
|
0.90
|
|
28
|
A phase II study of induction chemotherapy with gemcitabine plus S-1 followed by chemoradiotherapy for locally advanced pancreatic cancer.
|
Cancer Chemother Pharmacol
|
2009
|
0.89
|
|
29
|
A phase I study of combination chemotherapy with gemcitabine and oral S-1 for advanced pancreatic cancer.
|
Oncology
|
2005
|
0.89
|
|
30
|
Characteristics of 18 patients with hepatocellular carcinoma who obtained a complete response after treatment with sorafenib.
|
Hepatol Res
|
2014
|
0.88
|
|
31
|
Phase I and pharmacokinetic clinical trial of oral administration of the acyclic retinoid NIK-333.
|
Hepatol Res
|
2011
|
0.88
|
|
32
|
His595Tyr polymorphism in the methionine synthase reductase (MTRR) gene is associated with pancreatic cancer risk.
|
Gastroenterology
|
2008
|
0.87
|
|
33
|
Evaluation of acute intestinal toxicity in relation to the volume of irradiated small bowel in patients treated with concurrent weekly gemcitabine and radiotherapy for locally advanced pancreatic cancer.
|
Anticancer Res
|
2006
|
0.87
|
|
34
|
Transcatheter arterial infusion chemotherapy with a fine-powder formulation of cisplatin for advanced hepatocellular carcinoma refractory to transcatheter arterial chemoembolization.
|
Jpn J Clin Oncol
|
2011
|
0.86
|
|
35
|
A multicenter phase II study of S-1 for gemcitabine-refractory biliary tract cancer.
|
Cancer Chemother Pharmacol
|
2013
|
0.85
|
|
36
|
Prognostic factors in patients with hepatocellular carcinoma refractory or intolerant to sorafenib.
|
Oncology
|
2014
|
0.85
|
|
37
|
Four cases of pancreatic acinar cell carcinoma treated with gemcitabine or S-1 as a single agent.
|
Jpn J Clin Oncol
|
2009
|
0.85
|
|
38
|
Early phase II study of uracil-tegafur plus doxorubicin in patients with unresectable advanced biliary tract cancer.
|
Jpn J Clin Oncol
|
2006
|
0.85
|
|
39
|
Treatment efficacy/safety and prognostic factors in patients with advanced biliary tract cancer receiving gemcitabine monotherapy: an analysis of 100 cases.
|
Oncology
|
2010
|
0.85
|
|
40
|
Phase I study of combination chemotherapy using sorafenib and transcatheter arterial infusion with cisplatin for advanced hepatocellular carcinoma.
|
Cancer Sci
|
2014
|
0.84
|
|
41
|
Dose-volume histogram analysis of the safety of proton beam therapy for unresectable hepatocellular carcinoma.
|
Int J Radiat Oncol Biol Phys
|
2010
|
0.83
|
|
42
|
Do recurrent and metastatic pancreatic cancer patients have the same outcomes with gemcitabine treatment?
|
Oncology
|
2009
|
0.83
|
|
43
|
Phase I/II study of gemcitabine as a fixed dose rate infusion and S-1 combination therapy (FGS) in gemcitabine-refractory pancreatic cancer patients.
|
Cancer Chemother Pharmacol
|
2011
|
0.82
|
|
44
|
Phase I/II study of hepatic arterial infusion chemotherapy with gemcitabine in patients with unresectable intrahepatic cholangiocarcinoma (JIVROSG-0301).
|
Am J Clin Oncol
|
2011
|
0.82
|
|
45
|
Regorafenib in Japanese patients with solid tumors: phase I study of safety, efficacy, and pharmacokinetics.
|
Invest New Drugs
|
2013
|
0.82
|
|
46
|
Twenty-six cases of advanced ampullary adenocarcinoma treated with systemic chemotherapy.
|
Jpn J Clin Oncol
|
2014
|
0.81
|
|
47
|
Characterization of patients with advanced pancreatic cancer and high serum interleukin-6 levels.
|
Pancreas
|
2015
|
0.81
|
|
48
|
Small-field radiotherapy in combination with concomitant chemotherapy for locally advanced pancreatic carcinoma.
|
Radiother Oncol
|
2003
|
0.81
|
|
49
|
Survey of survival among patients with hepatitis C virus-related hepatocellular carcinoma treated with peretinoin, an acyclic retinoid, after the completion of a randomized, placebo-controlled trial.
|
J Gastroenterol
|
2014
|
0.80
|
|
50
|
Phase I study of TAC-101, an oral synthetic retinoid, in Japanese patients with advanced hepatocellular carcinoma.
|
Cancer Sci
|
2012
|
0.79
|
|
51
|
Hepatitis B Virus Reactivation during Treatment with Multi-Tyrosine Kinase Inhibitor for Hepatocellular Carcinoma.
|
Case Rep Oncol
|
2012
|
0.79
|
|
52
|
Efficacy of prophylactic minocycline treatment for skin toxicities induced by erlotinib plus gemcitabine in patients with advanced pancreatic cancer: a retrospective study.
|
Am J Clin Dermatol
|
2015
|
0.78
|
|
53
|
Neural invasion induces cachexia via astrocytic activation of neural route in pancreatic cancer.
|
Int J Cancer
|
2012
|
0.78
|
|
54
|
A phase II trial of transcatheter arterial infusion chemotherapy with an epirubicin-Lipiodol emulsion for advanced hepatocellular carcinoma refractory to transcatheter arterial embolization.
|
Cancer Chemother Pharmacol
|
2007
|
0.78
|
|
55
|
Transcatheter arterial embolization with zinostatin stimalamer for hepatocellular carcinoma.
|
Oncology
|
2002
|
0.78
|
|
56
|
Phase II study of combination chemotherapy with gemcitabine and cisplatin for patients with metastatic pancreatic cancer.
|
Jpn J Clin Oncol
|
2007
|
0.78
|
|
57
|
Phase I study of fixed dose rate infusion of gemcitabine in patients with unresectable pancreatic cancer.
|
Jpn J Clin Oncol
|
2005
|
0.78
|
|
58
|
Emerging drugs for biliary cancer.
|
Expert Opin Emerg Drugs
|
2013
|
0.78
|
|
59
|
Phase I and pharmacokinetic study of 5-fluorouracil administered by 5-day continuous infusion in patients with hepatocellular carcinoma.
|
Cancer Chemother Pharmacol
|
2001
|
0.77
|
|
60
|
Chemoradiotherapy for locally advanced pancreatic carcinoma in elderly patients.
|
Oncology
|
2005
|
0.77
|
|
61
|
Treatment outcome for systemic chemotherapy for recurrent pancreatic cancer after postoperative adjuvant chemotherapy.
|
Pancreatology
|
2012
|
0.77
|
|
62
|
Characteristic pattern of reactivation of hepatitis B virus during chemotherapy for solid cancers.
|
Dig Dis
|
2012
|
0.77
|
|
63
|
Current status of hepatocellular carcinoma treatment in Japan: case study and discussion-voting system.
|
Clin Drug Investig
|
2012
|
0.77
|
|
64
|
Successful everolimus treatment in a patient with advanced pancreatic neuroendocrine tumor who developed everolimus-induced interstitial lung disease on two occasions: a case report.
|
Chemotherapy
|
2013
|
0.77
|
|
65
|
[Chemotherapy for hepatocellular carcinoma].
|
Gan To Kagaku Ryoho
|
2004
|
0.77
|
|
66
|
Safety, tolerability, pharmacokinetics and antitumor activity of ganitumab, an investigational fully human monoclonal antibody to insulin-like growth factor type 1 receptor, combined with gemcitabine as first-line therapy in patients with metastatic pancreatic cancer: a phase 1b study.
|
Jpn J Clin Oncol
|
2014
|
0.76
|
|
67
|
Phase II study of uracil-tegafur in patients with metastatic pancreatic cancer.
|
Oncology
|
2002
|
0.76
|
|
68
|
C-Reactive Protein Level Is an Indicator of the Aggressiveness of Advanced Pancreatic Cancer.
|
Pancreas
|
2016
|
0.76
|
|
69
|
A Phase I study of MEDI-575, a PDGFRα monoclonal antibody, in Japanese patients with advanced solid tumors.
|
Cancer Chemother Pharmacol
|
2015
|
0.76
|
|
70
|
FP therapy for controlling malignant ascites in advanced pancreatic cancer patients.
|
Hepatogastroenterology
|
2007
|
0.76
|
|
71
|
Phase II study of cisplatin, epirubicin and continuous infusion of 5-fluorouracil in patients with advanced intrahepatic cholangiocellular carcinoma (ICC).
|
Hepatogastroenterology
|
2008
|
0.76
|
|
72
|
Transarterial infusion chemotherapy with cisplatin plus S-1 for hepatocellular carcinoma treatment: a phase I trial.
|
BMC Cancer
|
2014
|
0.75
|
|
73
|
Psychological states and coping strategies after bereavement among spouses of cancer patients: a quantitative study in Japan.
|
Support Care Cancer
|
2012
|
0.75
|
|
74
|
Phase I study of hyperfractionated radiation therapy with protracted 5-fluorouracil infusion in patients with locally advanced pancreatic cancer.
|
Oncology
|
2004
|
0.75
|
|
75
|
[Two cases of advanced extrahepatic bile duct cancer successfully treated by S-1 monotherapy].
|
Gan To Kagaku Ryoho
|
2007
|
0.75
|
|
76
|
[Chemotherapy for gallbladder cancer].
|
Nihon Shokakibyo Gakkai Zasshi
|
2013
|
0.75
|
|
77
|
[Transcatheter arterial chemoembolization with a lipophilic platinum complex SM-11355(miriplatin hydrate)--safety and efficacy in combination with embolizing agents].
|
Gan To Kagaku Ryoho
|
2010
|
0.75
|
|
78
|
Primary hepatocellular carcinoma detected long after tumor markers and lymph node metastases--beyond our vision?
|
Dig Dis Sci
|
2006
|
0.75
|
|
79
|
[5 -fluoropyrimidines for treatment of biliary tract cancers].
|
Nihon Rinsho
|
2006
|
0.75
|
|
80
|
Long-term administration of Wilms tumor-1 peptide vaccine in combination with gemcitabine causes severe local skin inflammation at injection sites.
|
Jpn J Clin Oncol
|
2010
|
0.75
|
|
81
|
Gemcitabine in patients with intraductal papillary mucinous neoplasm with an associated invasive carcinoma of the pancreas.
|
Pancreas
|
2013
|
0.75
|
|
82
|
A phase I/II study of combined chemotherapy with mitoxantrone and uracil/tegafur for advanced hepatocellular carcinoma.
|
Jpn J Clin Oncol
|
2010
|
0.75
|
|
83
|
Impaired mental health among the bereaved spouses of cancer patients.
|
Psychooncology
|
2012
|
0.75
|
|
84
|
[A three-week regimen of S-1 monotherapy reduced gastrointestinal toxicity and maintained efficacy in patients with gemcitabine-refractory advanced pancreatic cancer].
|
Gan To Kagaku Ryoho
|
2015
|
0.75
|
|
85
|
[S-1 monotherapy for pancreatic cancer].
|
Gan To Kagaku Ryoho
|
2006
|
0.75
|
|
86
|
Transarterial (Chemo)Embolization for Liver Metastases in Patients with Neuroendocrine Tumors.
|
Oncology
|
2017
|
0.75
|
|
87
|
[Non-surgical treatment for pancreatic cancer].
|
Nihon Shokakibyo Gakkai Zasshi
|
2006
|
0.75
|